Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verdiperstat for Multiple System Atrophy
NCT03952806Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in multiple system atrophy (MSA) comparing Verdiperstat with Placebo (2 arms). Primary endpoints: Change From Baseline in the Modified Unified Multiple System Atrophy Rating Scale Score at Week 48 and Number of Participants With Treatment-Emergent Adverse Events and Serious TEAEs up to 100 weeks. Started Jul 2019; status: completed.
02
Drugs
verdiperstat
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT03952806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952806.